ICB treatment in both shScr-ST and shIDO-ST groups increased Tregs out of total CD4+ T cells consistent with reports in human tumor treatment [59,60]; however, shIDO-ST treatment in combination with ICB prevented the level of Treg increase seen in the shScr-ST + ICB treatment group (Figure 6B). The gene discussed is CD4; the disease is neoplasm.